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High-frequency stimulation of the subthalamic
nucleus modifies the expression of vesicular
glutamate transporters in basal ganglia in a rat
model of Parkinson’s disease
Mathieu Favier1,2, Carole Carcenac1,2, Guillaume Drui1,2, Sabrina Boulet1,2, Salah El Mestikawy4,5,6,7
and Marc Savasta1,2,3*
Abstract
Background: It has been suggested that glutamatergic system hyperactivity may be related to the pathogenesis of
Parkinson’s disease (PD). Vesicular glutamate transporters (VGLUT1-3) import glutamate into synaptic vesicles and
are key anatomical and functional markers of glutamatergic excitatory transmission. Both VGLUT1 and VGLUT2 have
been identified as definitive markers of glutamatergic neurons, but VGLUT 3 is also expressed by non glutamatergic
neurons. VGLUT1 and VGLUT2 are thought to be expressed in a complementary manner in the cortex and the
thalamus (VL/VM), in glutamatergic neurons involved in different physiological functions. Chronic high-frequency
stimulation (HFS) of the subthalamic nucleus (STN) is the neurosurgical therapy of choice for the management of
motor deficits in patients with advanced PD. STN-HFS is highly effective, but its mechanisms of action remain
unclear. This study examines the effect of STN-HFS on VGLUT1-3 expression in different brain nuclei involved in
motor circuits, namely the basal ganglia (BG) network, in normal and 6-hydroxydopamine (6-OHDA) lesioned rats.
Results: Here we report that: 1) Dopamine(DA)-depletion did not affect VGLUT1 and VGLUT3 expression but
significantly decreased that of VGLUT2 in almost all BG structures studied; 2) STN-HFS did not change VGLUT1-3
expression in the different brain areas of normal rats while, on the contrary, it systematically induced a significant
increase of their expression in DA-depleted rats and 3) STN-HFS reversed the decrease in VGLUT2 expression
induced by the DA-depletion.
Conclusions: These results show for the first time a comparative analysis of changes of expression for the three
VGLUTs induced by STN-HFS in the BG network of normal and hemiparkinsonian rats. They provide evidence for
the involvement of VGLUT2 in the modulation of BG cicuits and in particular that of thalamostriatal and
thalamocortical pathways suggesting their key role in its therapeutic effects for alleviating PD motor symptoms.
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Background
It is long recognized that the degeneration of dopaminergic
neurons induces an abnormal activation of glutamate
systems in the basal ganglia (BG) that is central to the
pathophysiology of Parkinson’s disease (PD) [1-4].
Glutamate mediated mechanisms are also thought to
play a role in the development of dyskinesias with long-
term administration of L-3,4-dihydroxyphenylalanine
(L-DOPA), the most efficient treatment for PD. Many
experimental studies also evidence that dopamine de-
nervation induces an increase in corticostriatal glutamate
[5-11] and that L-DOPA-induced dyskinesia (LID) are
linked to BG network glutamate transmission abnormal-
ities [12,13]. Microdialysis studies have suggested that
dopamine lesion may also increase glutamate transmis-
sion in the BG output structures, substantia nigra pars
reticulata (SNr) [5,14-16] and entopeduncular nucleus
[6], presumably as a result of the abnormal activation of
the subthalamic nucleus (STN) [17].
Three subtypes of vesicular glutamate transporters have
been identified: VGLUT1, 2 and 3 [18]. These transporters
mediate glutamate uptake inside presynaptic vesicles and
are anatomical and functional markers of glutamatergic
excitatory transmission [19-25]. VGLUT1-3 are very
similar in structure and function, but are used by
different neuronal populations. VGLUT1 and VGLUT2
are expressed by the cortical and subcortical neurons
respectively. VGLUT3 is expressed by nonglutamatergic
neurons, such as cholinergic striatal interneurons, a
GABAergic interneuron subpopulation from the cortex
and hippocampus and serotoninergic neurons from the
dorsal and medial raphe nuclei [22,26].
Since the 1990s, High Frequency Stimulation (HFS)
of the STN has become an effective surgical treatment
of late-stage Parkinson’s disease (PD), improving all
motor symptoms in PD patients, particularly in those
who experience motor fluctuations [27-29]. However,
the mechanisms underlying the improvement in symp-
toms remain unclear [30-32]. Beyond its local effect on
STN activity, we know that, by activating axons, STN-
HFS may generate widespread and heterogeneous distal
effects throughout the BG network [32,33]. Indeed, we
have already reported in previous studies that in intact or
6-OHDA (6-hydroxydopamine)-lesioned rats, STN-HFS
increases extracellular glutamate in the striatum, the
globus pallidus and the SNr [14-16,34].
The present study analyzed the effects of DA depletion
and for the first time those of STN-HFS on VGLUT1-3
expression in several BG nuclei, by using immunoradioau-
tography with affinity-purified rabbit VGLUT1, VGLUT2
or VGLUT3 antiserum.
We found that DA-depletion did not affect VGLUT1 and
VGLUT3 expression in almost all BG structures studied
while that of VGLUT2 significantly decreased. Interestingly,
STN-HFS did not affect VGLUT1-3 expression in normal
rats, but systematically increased their expression in most
of the BG nuclei studied in DA-depleted animals.
According to the changes of VGLUT1-3 expression
observed and to their known anatomical localization, we
suggest that STN-HFS may achieve its therapeutic effect,
at least in part, through normalization of the thalamos-
triatal and thalamocortical pathways.
Methods
Animals
Adult (5 to 7 weeks old) male Sprague–Dawley rats
(Janvier, Le Genest St Isle, France), weighing 180 to
270 g, were housed in an animal room on a 12-hour
light/dark cycle, with food and water supplied ad libitum.
This study was carried out in strict accordance with
the recommendations of the European Community
Council Directive of 24 November 1986 (86/609/EEC)
concerning the care of laboratory animals, French Ministry
of Agriculture regulations (Direction Départementale de la
Protection des Populations, Préfecture de l’Isère, France,
Grenoble Institute of Neuroscience, agreement number: A
38-516-10-008; Marc Savasta, permit number 38-10-08,
Carole Carcenac permit number 38-10-23) and French
guidelines for the use of live animals in scientific investi-
gations. The protocol was approved by the Committee
on the Ethics of Animal Experiments of the “Grenoble
Institute of Neuroscience ethical committee” agreement
number 04. All surgery was performed under a mixture
of xylazine and ketamaine and all efforts were made to
minimize the number of animal used and their suffering.
All operated rats were intraperitoneally treated with
Rimadyl (1 ml.kg-1) to prevent post-surgery suffering.
Lesion procedure
Forty rats (n = 40) were anesthetized with a mixture of
xylazine (10 mg.kg-1, intraperitoneal) and ketamine
(100 mg.kg-1, intraperitoneal) and secured in a Kopf
stereotaxic apparatus (Phymep, Paris, France). All ani-
mals received desipramine (25 mg/kg s.c.) pretreat-
ment, to protect noradrenergic neurons. Lesioned
animals (n = 20) received a unilateral injection of 9 μg
of 6-hydroxydopamine (6-OHDA) (Sigma, St. Quentin-
Fallavier, France) dissolved in 3 μl of 0.9% sterile NaCl
supplemented with 0.2% ascorbic acid, administered at
a flow rate of 0.5 μl · min-1 to the left SNc. An identical
procedure was used for controls (n = 20) but with the
injection of NaCl 0.9%. The stereotaxic coordinates for
the injection site relative to the bregma were as
follows: anteroposterior (AP), -5.3 mm; lateral (L),
+2.35 mm; dorsoventral (DV), -7.5 mm, with the inci-
sor bar at 3.3 mm below the interaural plane, according
to the stereotaxic atlas of Paxinos and Watson [35].
After injections, animals were kept warm and allowed
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to recover from the anesthetic before being returned to
the animal house for three weeks until the stimulation
experiments. This time interval was left to allow the
DA system degeneration induced by the neurotoxin to
stabilize.
Implantation of the stimulation electrode
Rats from the two experimental groups (sham-operated
controls, n = 20, and 6-OHDA lesioned, n = 20) were first
anesthetized by the inhalation (1 l.min-1) of a mixture of
3% isoflurane in air (the air used being composed of 22%
O2, 78% N2) and mounted in a stereotaxic frame (David
Kopf Instruments, Tujunga, CA). The dorsal skull was
exposed and holes were drilled for the implantation of
the stimulation electrode into the left STN. During the
implantation and stimulation procedure, anesthesia was
maintained with an inhaled mixture of 1% isoflurane in
air (1 l.min-1) and body temperature was maintained at
37°C with a feedback-controlled heating pad (Harvard
Apparatus, Edenbridge, UK). Stereotaxic coordinates
were chosen according to the atlas of Paxinos and
Watson [35] and were as follows relative to the bregma:
AP, -3.7 mm; L, +2.4 mm; and DV, -7.8 mm as previously
described [14-16,34,36].
Electrical stimulation
For electrical stimulation, we used a concentric stimulating
bipolar electrode (SNEX 100, Rhodes Medical Instruments,
Woodland Hills, CA), with an outer diameter of 250 μm
and a distance between the poles of 1 mm. Stimuli were
delivered under anesthesia during 4 hours with a World
Precision Instrument (Stevenage, UK) acupulser and
stimulus isolation units giving a rectangular pulse. This
duration of stimulation (> 1 h) was chosen to be sure that
the proteic expression of VGLUTs can be detected and
stabilized and almost corresponds to that used in previous
studies analyzing mRNA levels of different target proteins
of basal ganglia circuits [37]. As previously reported, the
stimulation parameters (130 Hz, 60 μs, 200 μA) matched
those routinely used in Parkinsonian patients [14,34,36].
At the end of each experiment, an electrical lesion was
created in the STN so that the position of the electrode
could be checked post-mortem. In control rats (sham-
operated and 6-OHDA-lesioned) the stimulation was
never switched “on”.
Histology
At the end of the electrical stimulation, all animals were
perfused transcardially with 0.9% saline, under chloral
hydrate anesthesia. Brains were rapidly removed and frozen
in cooled (−40°C) isopentane, then stored at −20°C. Serial
frontal sections (14-μm thick) were cut with a cryostat
(Microm HM 500, Microm, Francheville, France), collected
on microscopic slides and stored at −20°C. Tissue sections
from different BG nuclei and related structures (stri-
atum (caudate-putamen), nucleus accumbens, motor
and somatosensory cortices, thalamus (VL/VM), sub-
thalamic nucleus, globus pallidus and substantia nigra
pars reticulata (SNr)) were selected to analyze changes
in VGLUT expression.
The correct location of the stimulation electrode was
checked by collecting several subthalamic tissue sections
(n = 12 sections per stimulated rat) (14 μm thick from
AP, -3,6 to −4,3 mm relative to the bregma, Paxinos and
Watson, [35]) and counterstaining with cresyl violet.
The tip of the electrode was systematically implanted
directly in the STN at the top of its dorsal part. These
histological controls were systematically carried out for
all the animals in each experimental group. All animals
with incorrectly positioned stimulation electrodes were
excluded (controls, n = 3 and 6-OHDA lesioned, n = 4).
TH-immunohistochemistry
We assessed the extent of the dopaminergic denervation
induced by nigral 6-OHDA injection by TH immunostain-
ing on striatal and nigral sections from the fixed brains of
lesioned animals. TH immunostaining was carried out as
previously described [14]. Briefly, striatal and nigral tissue
sections from 6-OHDA-lesioned rats were mounted on
silane-coated microscope slides. Tissue sections were
postfixed in 4% paraformaldehyde, thoroughly washed
with Tris buffered-saline (TBS, 0.1 M, pH 7.4) and incu-
bated for 1 hour in 0.3% Triton X-100 in TBS (TBST) and
3% normal goat serum (NGS, Sigma-Aldrich, St Quentin
Fallavier, France). They were then incubated with primary
antisera diluted in TBST supplemented with 1% normal
goat serum (NGS) for 24 h, at 4°C. The antiserum was
diluted 1:500 for TH staining (mouse monoclonal anti-
body; Chemicon, Temecula, CA). Antibody binding
was detected with avidin-biotin-peroxidase conjugate
(Vectastain ABC Elite, Vector Laboratories, Burlingame,
CA), with 3, 3’-diaminobenzidine as the chromagen. The
detection reaction was allowed to proceed for one to
three minutes, as previously described. Sections were
dehydrated in a series of graded ethanol solutions,
cleared in xylene, mounted in DPX (DBH Laboratories
Supplies, Poole, UK) and covered with a coverslip for
microscopy.
VGLUT 1–3 immunoradioautography
Tissue sections were air-dried, post-fixed by immersion in
fixative (4% PFA), and then washed in PBS. Nonspecific
binding sites were saturated by incubation with 3% bovine
serum albumin (BSA) in PBS, 1% NGS and 2 mM NaI
(buffer A). Sections were incubated overnight at 4°C in
buffer A supplemented with affinity-purified rabbit
VGLUT1, VGLUT2 or VGLUT3 antiserum (dilution 1/
10000 for VGLUT1 and VGLUT2, 1/5000 for VGLUT3,
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from Dr Salah El Mestikawy), and then for 1 hour with an
affinity-purified goat anti-rabbit [125I] IgG (0.25 μCi/ml,
Perkin Elmer, Paris, France) in buffer A supplemented
with 0.02% sodium azide. The sections were rinsed in
water, dried and placed against X-ray films (Biomax MR,
Kodak) for 9 to 11 days.
The specificity of all antisera used in this study have
been previously validated by our group (Gras et al. [22],
[38]; Herzog et al. [23], [26]). For each labeled section, a
background value was estimated by measuring optical
density in the corpus callosum, since this structure is
devoided of specific staining for VGLUT 1–3 antibodies.
This background value was then systematically subtracted
from the optical density values obtained for each corre-
sponding section.
Quantification and statistical analysis
For the evaluation of the extent of DA-denervation,
striatal and nigral TH immunostained sections were
directly processed by using the Calopix software of the
computerized image analysis system (TRIBVN, 2.9.2
version, Châtillon, France). Six TH-immunostained sec-
tions from each structure (striatum and SNc) and for
each rat were used for quantification. The loss of TH
immunostaining in the SNc or in the striatum was
evaluated by comparing the total surface of both struc-
tures, as revealed by the TH immunolabelling, in normal
and lesioned animals.
For quantification of VGLUT1-3 contents, four AP levels
(+1, -0.92, -3.8 and −5.5 mm relative to bregma (Paxinos et
Watson, [35])) were choosen. For each rat, three stained
sections of the same AP level were used for quantification
and the triplicate OD values obtained for each structure
analyzed were averaged. Immunoradioautograms obtained
from X-ray films were analyzed with Autoradio V4.03
software (SAMBA Technologies, Meylan, France). Values
of optical densities measured from each structure analyzed
are expressed as a mean ± standard error (SEM) in Table 1.
Histograms presented in figures show the mean ± standard
error of the mean (SEM) of optical densities expressed as a
percentage of control values. Data were analyzed for each
brain structure by Kruskal-Wallis tests with SigmaStat 3.1
software. Post-hoc analyses were carried out with the
Dunn’s method.
Results and discussion
Histological controls of the extent of the dopamine lesion
and of electrode location
Three weeks after the unilateral injection of 6-OHDA,
all lesioned animals presented a substantial loss of TH
immunostaining in the ipsilateral SNc and the striatum
(caudate-putamen nucleus), as shown by comparison
with the contralateral side (Figure 1A, B) or with control
animals. An analysis of densitometric measurements of
TH immunostaining showed an absence of statistical
difference between the two lesioned groups (non stimu-
lated and stimulated).
In DA-depleted animals, the loss of SNc TH+ neurons
was evaluated by comparing the total SNc surface on the
intact side with the homologous area on the lesioned side.
A loss of 92 ± 5% (p < 0.001) of TH immunolabeled
surface was measured. In the striatum of the same rats,
the loss of DA nerve terminals, as revealed by TH immu-
nostaining mainly affected the dorsal part of the striatum
(Figure 1B). This loss affected around 83 ± 4% of the
striatal surface as compared to the total striatal surface of
the control side. In this denervated striatal area, TH
immunolabeling, as evaluated by a mean of densitometric
values, was decreased by 85 ± 5% (p < 0.001) when com-
pared to the controlateral intact side.
The correct implantation of the stimulation electrode in
the STN is illustrated in Figure 1C-E. Figure 1E shows, at
a higher magnification, the small electrical lesion (asterisk)
created at the end of the experiment, indicating the point
stimulated.
Regional distribution of VGLUT1-3 in control rats (without
lesioning and stimulation)
VGLUT1-3 expression was qualitatively analyzed in con-
trol rats that had been neither lesioned nor stimulated, to
ensure the validity and specificity of the immunoradioau-
tographical staining. Immunoradioautograms from the
different sections showed a distribution of VGLUT1-3
similar to that previously reported [26,39], confirming the
validity of our VGLUT1-3 staining procedure and the lack
of cross-reactivity between the antibodies used.
VGLUT1 immunostaining was dense in almost all the
structures studied, including, especially, the striatum,
nucleus accumbens, cortex, the motor part of the
thalamus (VL/VM) and hippocampus. By contrast, no
VGLUT1 labeling was found in the globus pallidus, the
substantia nigra and in most of the brainstem (Figure 2
E-H).
VGLUT2 proteins were detected in almost the same set
of structures as VGLUT1 although the density of VGLUT2
immunostaining was slightly lower than that for VGLUT1
in striatal, cortical and thalamic areas, whereas the oppos-
ite was observed in many sub-cortical structures. These
data are consistent with the well-described complementary
pattern of expression of VGLUT1 and VGLUT2 in the rat
brain. VGLUT2 staining, unlike that for VGLUT1, was
detectable in the substantia nigra pars reticulata, hypothal-
amic nuclei and midbrain, which displayed widespread
staining. Different, complementary patterns of immuno-
staining for VGLUT1 and VGLUT2 were observed in
the hippocampus. The density of VGLUT2 proteins was
highest in layers IV and VI of the cortex and in the
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Table 1 Effect of 6-OHDA-lesion and STN-HFS on bilateral changes of optical density measurements of immunoreactive signals for VGLUT1-3
VGLUT1 VGLUT2 VGLUT3
Ipsilateral side Controlateral side Ipsilateral side Controlateral side Ipsilateral side Controlateral side
A Controls 6-OHDA Controls 6-OHDA Controls 6-OHDA Controls 6-OHDA Controls 6-OHDA Controls 6-OHDA
CPu 51,35 (±3,2) 53,33 (±1,9) 48,78 (±3,4) 52,59(±1,7) 20,15 (±2,38) 12,64*(±1,5) -37% 19,76 (±2,3) 13,38*(±0,6) -33% 16, 65(±0,8) 18,15 (±1,7) 15,37 (±0,8) 16, 33 (±3,1)
PM Cx 55,54 (±3,3) 48,3 (±2,1) 55,81 (±2,9) 48,07 (±2,8) 18,56 (±1,7) 10,93*(±0,6) -42% 18,5 (±2,1) 11,12*(±0,6) -40% 14,34 (±0,9) 13,09 (±2,4) 14,39 (±0,9) 13, 02 (±2,5)
SS Cx 45,93 (±3) 35,37 (±1,6) 45,93 (±1,6) 38,93 (±1,6) 15,79 (±1,81) 9,22*(±0,4) -42% 16,44 (±1,8) 10,57*(±0,6) -36% 12,01 (±0,6) 10,28 (±2,1) 12,89 (±0,7) 11,63 (±2,4)
Acb 54,15 (±2,8) 63,43 (±2,8) 51,52 (±3,6) 59,65 (±3,1) 22,55 (±2,7) 13,56*(±2,1) -40% 22,14 (±2,6) 13,91*(±2,1) -47% 18,84 (±0,9) 23,33 (±1,1) 19,04 (±1,1) 23 (±1,2)
Thalamus 41,18 (±3,4) 34,15 (±1,7) 41,86 (±3,3) 32,47 (±1,1) 16,83 (±2,3) 8,85*(±0,4) -48% 17,49 (±2,4) 9,05*(±0,7) -48% 11,38 (±0,5) 9,85 (±1,3) 11,43 (±0,5) 9,79 (±1,1)
STN 21,13 (±2,7) 23, 56 (±4,6) 19,25 (±2,5) 20,65 (±4,2) 16,83 (±2,1) 7,66*(±1,3) -55% 15,53 (±2,3) 9,32*(±0,5) -40% ND ND ND ND
GP ND ND ND ND 12,78 (±1,9) 7,97(±1) 13,39 (±1,7) 8,83 (±1,1) ND ND ND ND
SNr ND ND ND ND 51,1 (±2,4) 11,26*(±0,3) -25% 15,76 (±2,2) 11,39*(±0,5) -28% ND ND ND ND
Ipsilateral side Controlateral side Ipsilateral side Controlateral side Ipsilateral side Controlateral side
B 6-OHDA 6-OHDA +
STN-HFS
6-OHDA 6-OHDA +
STN-HFS
6-OHDA 6-OHDA +
STN-HFS
6-OHDA 6-OHDA +
STN-HFS
6-OHDA 6-OHDA +
STN-HFS
6-OHDA 6-OHDA +
STN-HFS
CPu 53,33
(±1,8)
65,07*(±3,4)
+22%
52,59 (±1,7) 64,43(±3,2)
+23%
12,64 (±1,5) 17,81*(±1,4)
+41%
13,38 (±0,6) 17,61*(±1,8)
+32%
18,15
(±1,7)
26,13*(±2,9)
+44%
16,33
(±3,1)
24,88*(±1,8)
+53%
PM Cx 48,3 (±2,2) 63,08*(±3,3)
+31%
48,07
(±2,8)
64, 79*(±3,5)
+35%
10,93 (±0,6) 16,93*(±1,6)
+55%
11,12 (±0,6) 16,86*(±1,8)
+52%
13,09
(±2,4)
20*(±1,9)
+53%
13,02
(±2,5)
16,62*(±1,7)
+51%
SS Cx 35,75 (±1) 54,25*(±3,8)
+52%
38,93
(±1,6)
55,08*(±3,8)
+41%
9,22 (±0,4) 14,03*(±1,4)
+52%
10,57 (±0,6) 13,38*(±1,6)
+27%
10,28
(±2,1)
20,44*(±2,1)
+99%
11,63
(±2,4)
16,78*(±1,4)
+44%
Acb 63,43 (±2,8) 65,39 (±3,9) 59,65 (±4,1) 65,06 (±4,1) 13,56 (±2,1) 20,25*(±1,3)
+49%
13,91 (±2,1) 18,78*(±1,2)
+35%
23,23
(±1,1)
31,7* (1,2)
+36%
23 (±1,2) 31,89*(±1,2)
+38%
Thalamus 34,15
(±1,7)
48,1*(±3,8)
+41%
32,47
(±1,1)
46,37 (±3,6)
+43%
8,85 (±0,4) 14,63*(±1,6)
+65%
9,05 (±0,7) 13,5*(±1,5)
+449%
9,85 (±1,3) 20,3*(±1,6)
+106%
9,79 (±1,1) 19,38*(±2,5)
+98%
STN 23,56 (±4,6) 17,78 (±2,6) 20,65 (±4,2) 19,34 (±3) 7,66 (±1,3) 14,79*(±1,5)
+93%
9,32 (±0,5) 15,94*(±1,9)
+71%
ND ND ND ND
GP ND ND ND ND 7.97 (±1) 10,18 (±0,9) 8,83 (±1,1) 9,61 (±1) ND ND ND ND
SNr ND ND ND ND 11,26 (±0,3) 15,84*(±1,3)
+41%
11,39 (±0,5) 16,64*(±1,4)
+46%
ND ND ND ND
A, Modifications of VGLUT1-3 expression induced by unilateral 6-OHDA-lesion of SNc (control rats, n = 9; 6-OHDA rats, n = 6). *p<0.05, vs control group.
B, Modifications of VGLUT1-3 expression induced by unilateral STN-HFS in 6-OHDA lesioned rats (6-OHDA rats, n = 6; 6-OHDA rats + STN-HFS, n = 10). *p<0.05, vs non stimulated 6-OHDA-lesioned group. Values of
optical densities measurements are expressed as a mean ± standard error (SEM). Data were analyzed for each brain structure by Kruskal-Wallis tests with SigmaStat 3.1 software. Post-hoc analyses were carried out with
the Dunn’s method. Bold numbers correspond to significant differences. Ipsilateral side: related to the lesion and/or stimulation side; Controlateral side: related to the lesion and/or stimulation side; Acb,
Accumbens nucleus; CPu, Caudate Putamen (striatum); GP, Globus Pallidus; PM Cx, Premotor Cortex; SNr, Substantia nigra pars reticulata; SS Cx, Somatosensory Cortex; STN, Subthalamic nucleus; Thalamus (VL/VM).
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hypothalamus, the central gray matter and the superior
colliculus (Figure 2 I-L).
VGLUT3 staining was weaker than that for VGLUT1
and VGLUT2, but was also observed in many different
areas. VGLUT3 levels were moderate in the striatum,
but high in the hippocampus, with a complementary
distribution for VGLUT1 and VGLUT2 (Figure 2M-P).
Effects of 6-OHDA-lesion and/or STN-HFS on VGLUT1-3
expression
DA lesion and STN stimulation were unilaterally performed
in this study. However, we found similar changes of
VGLUTs expression on both sides, as revealed by the op-
tical density measurements of immunoreactive signals for
VGLUT1-3 in all structures examined (see Table 1). In
order to simplify the presentation of our data, we decided
to only show the results obtained from the ipsilateral side
(the lesioned and/or stimulated side) on Figures 3 and 4. As
precised in materials and methods, changes in VGLUTs ex-
pression induced by 6-OHDA lesion and STN stimulation
were first analyzed by Kruskal-Wallis tests with SigmaStat
3.1 software. Results of these tests for each brain structure
are presented in legends of Figures 3 and 4. Post-hoc ana-
lyses were then carried out with the Dunn’s method.
Effect of the 6-OHDA-lesion on VGLUT1-3 expression
DA depletion did not affect VGLUT1 and VGLUT3
expression whatever the brain structure analyzed. Slight
changes were observed in the striatum, nucleus accum-
bens, somatosensory cortex and thalamus (VL/VM), but
they were not statistically significant (Table 1, Figures 3
and 4, white versus dark grey histograms).
By contrast, 6-OHDA lesioning induced a significant
decrease in VGLUT2 expression of nearly 50% with
respect to that in sham-operated rats (Figures 3 and 4).
This decrease was particularly strong in the STN, thalamus
(VL/VM) (Figure 4B), and cortical areas (Figure 3B)
which displayed decreases of 55%, 48% and 42% with
respect to control (non-lesioned) rats, respectively (p <
0.05, n = 6).
Effect of STN-HFS on VGLUT1-3 expression in sham-
operated control (non-lesioned) rats and in 6-OHDA-
lesioned animals
No significant change in VGLUT1-3 expression was
detected after four hours of STN-HFS in sham-operated
control rats (non-lesioned) rats. Levels of VGLUT1-3 ex-
pression were similar between the two experimental groups
(non-lesioned rats with and without STN stimulation) in all
different structures studied, as show in Figures 3 and 4.
On the contrary, STN-HFS induced a marked increase in
VGLUT1-3 expression in 6-OHDA-lesioned rats. This
increase affected almost all the brain structures studied
(Table 1, Figures 3 and 4). VGLUT1 levels were always
higher for all brain areas studied in stimulated 6-OHDA
rats when compared to non-stimulated 6-OHDA-rats
Figure 1 Photographs of TH-immunostained coronal rat-brain sections at the nigral (A) and striatal (B) levels and of cresyl
violet-stained coronal rat-brain sections at subthalamic (C, D and E) levels in 6-OHDA-lesioned rats. Note, on the lesioned side (left), the
loss of dopaminergic cells in the SNc (A) and the loss of dopaminergic terminals in the striatum (B). Note also the correct implantation of the
stimulation electrode within the STN (C, D, E). C, The arrow indicates the electrode track. E, The asterisk indicates the point of stimulation. CPu:
Caudate Putamen; Hip, Hippocampus; SNc, Substantia nigra pars compacta; SNr, Substantia nigra pars reticulata; STN, Subthalamic nucleus; VTA,
Ventral Tegmental Area. Scale bar, 0.75 mm.
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except for the nucleus accumbens (Acb) and STN
(Figure 3A, a-d, for examples of autoradiographs and
Figure 4A, a-d). The largest differences were found in the
somatosensory cortex (+52%) and the motor part of the
thalamus (VL/VM) (+41%) (p < 0.05, n = 10). For many
brain structures analyzed, VGLUT1 levels measured in
stimulated 6-OHDA-rats were comparable to those de-
tected in control (without lesion and stimulation) rats.
Interestingly, for the striatum and the thalamus (VL/VM),
VGLUT1 levels remained moderately overexpressed versus
controls (+27%, p < 0.05 and +17%, p < 0.05, respectively,
n = 10) (Figures 3A, a-d, and 4A, a-d).
STN-HFS induced a significant increase in VGLUT2
expression in all structures studied in 6-OHDA-
lesioned rats when compared to non-stimulated 6-
OHDA-rats. However this increase did not affect the
globus pallidus. (Figures 3B, e-h and 4B, e-h). Thus,
STN-HFS more or less completely reversed the decrease
in VGLUT2 expression induced by the DA-depletion in
all structures analyzed.
Figure 2 Regional distribution of VGLUT1-3 proteins in control (without lesion and stimulation) rats. A-D, Schematic diagrams adapted
from the stereotaxic atlas of Paxinos and Watson [1982]. E-P, Photographs of immunoradioautograms obtained by incubating coronal rat-brain
sections of control rats (non lesioned and non stimulated) with affinity-purified anti-VGLUT1 (E-H), anti-VGLUT2 (I-L) and anti-VGLUT3 (M-P)
antisera and then with anti-rabbit [125I] IgG. Note the different distributions of the three VGLUTs in the brain structures studied. Acb, Accumbens
nucleus; Amy, Amygdaloid nucleus; CPu, Caudate Putamen; Cg, Cingulate cortex; GP, Globus Pallidus; Hip, Hippocampus; PM Cx, Premotor Cortex;
SNr, Substantia nigra pars reticulata; SS Cx, Somatosensory Cortex; STN, Subthalamic nucleus; Tha, Thalamus (VL/VM). Scale bar, 0.4 mm.
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STN-HFS induced a strong upregulation of VGLUT3
expression in 6-OHDA-lesioned rats (Figures 3C, i-l and
4C, i-l). Interestingly, this effect was particularly marked in
the thalamus (VL/VM) (+106% versus non-stimulated
6-OHDA-lesioned rats, p < 0.05, n = 10) and the somato-
sensorial cortex (+99% versus non-stimulated 6-OHDA-
lesioned rats, p < 0.05, n = 10).
Discussion
The key findings of this study were: 1) DA depletion
decreased VGLUT2 (−40 to -50%) in all brain structures
studied; 2) STN-HFS did not affect VGLUT1-3 expression
in control (sham-operated) rats whatever the brain struc-
ture analyzed; 3) STN-HFS increased VGLUT1-3 expres-
sion in 6-OHDA-lesioned rats in almost all structures
Figure 3 Effects of 6-OHDA-lesion and STN-HFS on striatal and cortical VGLUT1-3 expression. A-C, Histograms show the mean ± standard
error of the mean (SEM) of optical density values expressed as a percentage of values of control rats (non lesioned and non stimulated). Data
were analyzed for each brain structure by Kruskal-Wallis tests with SigmaStat 3.1 software. Post-hoc analyses were carried out with the Dunn’s method.
Kruskal-Wallis tests (VGLUT1, CPu, p = 0.024; Acb, p = 0.05; PMCx, p = 0.049; SSCx, p = 0.02), (VGLUT2, CPu, p = 0.009; Acb, p = 0.002; PMCx, p = 0.012;
SSCx, p = 0.002), (VGLUT3, CPu, p = 0.003; Acb, p<0.001; PMCx, p = 0.043; SSCx, p = 0.002). a-l, Photographs of immunoradioautograms obtained by
incubating coronal rat-brain sections with affinity-purified anti-VGLUT1 (a-d), anti-VGLUT2 (e-h) and anti-VGLUT3 (i-l) antisera and then with 125I-labeled
anti-rabbit IgG. Acb, Accumbens nucleus; CPu, Caudate putamen; PM Cx, Premotor cortex; SS Cx, Somatosensory Cortex. *, controls vs 6-OHDA rats; #,
controls vs 6-OHDA + STN-HFS rats; Δ, 6-OHDA rats vs 6-OHDA + STN-HFS rats: p < 0.05. Scale bar, 0.4 mm.
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analyzed. Thereby STN-HFS: i) normalized VGLUT2 levels
after the decrease induced by DA depletion, and ii) signifi-
cantly increased VGLUT3 levels above those detected in
control animals. This was also true for VGLUT1 levels but
only for the striatum.
This remodeling suggests that the mode of action of
STN-HFS results from a global effect on basal ganglia
network and related structures and that its therapeutic
efficacy may to be linked, at least in part, to the
normalization of thalamostriatal and thalamocortical
neurotransmissions.
Bilateral effects of unilateral DA lesioning and STN-HFS
on VGLUT expression
As stated above, unilateral DA lesioning and STN-HFS
caused similar changes in VGLUT expression on both
Figure 4 Effects of 6-OHDA-lesion and STN-HFS on thalamic, pallidal and nigral VGLUT1-3 expression. A-C, Histograms show the mean ±
standard error of the mean (SEM) of optical density values expressed as a percentage of values of control rats (non lesioned and non stimulated).
Data were analyzed for each brain structure by Kruskal-Wallis tests with SigmaStat 3.1 software. Post-hoc analyses were carried out with the
Dunn’s method. Kruskal-Wallis tests: (VGLUT1, Thalamus VL/VM, p = 0.036; STN, p = 0.536), (VGLUT2, Thalamus (VL/VM); p = 0.036; STN, p = 0.015;
SNr, p = 0.049; GP, p = 0.048), (VGLUT3, Thalamus (VL/VM), p<0.001. a-l, Photographs of immunoradioautograms obtained by incubating coronal
rat-brain sections with affinity-purified anti-VGLUT1 (a-d), anti-VGLUT2 (e-h) and anti-VGLUT3 (i-l) antisera and then 125I-labeled anti-rabbit IgG. GP,
Globus Pallidus; SNr, Substantia nigra pars reticulata; STN, Subthalamic nucleus; Tha, Thalamus (VL/VM). *, controls vs 6-OHDA rats; #, controls vs
6-OHDA + STN-HFS rats; Δ, 6-OHDA rats vs 6-OHDA + STN-HFS rats: p < 0.05. Scale bar, 0.4 mm.
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sides of the brain. Bilateral effects of unilateral DA lesion-
ing have already been reported in the striatum for tissue
concentrations of glutamate [9], extracellular glutamate
content assessed by microdialysis or voltammetry [34,40],
glutamate receptor mRNA [41] and the glial glutamate
transporter GLT-1 [42]. Similarly, unilateral STN-HFS has
been reported to induce bilateral increases in striatal and
nigral glutamate content [14,15,34]. These bilateral effects
may result from crossed glutamatergic projections from
the cortex or the thalamus (VL/VM) innervating the BG
on the contralateral side, consistent with cross-talk in
cortico-BG-cortical loops [42].
Effect of 6-OHDA-SNc-lesioning on VGLUT expression
We found here that 6-OHDA-lesions had no effect on
VGLUT1 or VGLUT3 levels in any of the structures
studied. By contrast, VGLUT2 levels decreased significantly
three weeks after lesioning. At first glance, our observa-
tions contrast with previous reported data showing that
dopamine depletion is associated with an increase in
synaptic glutamate release [43-45] and with high striatal
extracellular glutamate levels and glutamatergic activity
[9,11,34,44,46-48] and greater thalamostriatal activity
[48,49], two to four weeks after lesioning of nigral
dopaminergic neurons. However, other studies have
reported an absence of change in glutamate levels [50].
These differences may be accounted for by differences
in the extent of the dopamine lesion, lesion sites,
methodologies and time courses. We cannot exclude the
possibility that different cellular mechanisms under-
lie presynaptic glutamate processes and extracellular
glutamate release after lesioning. Indeed, striatal extra-
cellular glutamate levels have been reported to depend
on a complex balance between vesicular release and
non vesicular release via glutamate transporters on
both neurons and glia and the cysteine-glutamine anti-
porter [50,51]. Dopamine depletion leads to complex,
biphasic changes in striatal glutamatergic transmission
over the first few weeks, possibly stabilizing over three
months. Contradictory data have been reported, for
the cysteine-glutamate antiporter [52] and glial trans-
porters [42,53,54] for example.
Furthermore, the changes in VGLUTs expression in-
duced by 6-OHDA lesions are also complex. VGLUT1
levels increase in the three weeks following the injection
but then decrease, whereas VGLUT2 levels decrease
and then normalize [42,55-57]. In monkeys, MPTP
treatment increases VGLUT1 expression but does not
affect VGLUT2 levels [53,58]. In postmortem samples
of Parkinsonian patients VGLUT1 and VGLUT2 levels
are increased in the putamen while VGLUT1 levels is
lowered in the prefrontal and temporal cortex [56].
However, the decrease in VGLUT2 levels observed
here in all the brain structures of 6-OHDA rats closely
parallels the thalamic hypoactivity induced by the strength-
ening of GABAergic inputs from the SNr and EP/GPi by
the STN overactivity observed in DA-depleted BG net-
works [59]. Furthermore, neuronal degeneration has been
observed postmortem in the thalamic nuclei of PD patients
[60] and in the parafascicular nucleus in 6-OHDA-lesioned
rats [49]. VGLUT2 is massively expressed by thalamic
nuclei [61] and have be postulated as selective marker of
thalamo-striatal activity [62]. This observation support the
notion of a potential decreased glutamatergic afferences
from the thalamus (VL/VM).
Effect of STN-HFS on VGLUT1-3 expression in control and
6-OHDA-lesioned rats
STN-HFS had no effect on VGLUT1-3 expression in any
of the brain structures studied in control rats. This sug-
gests that in the absence of dopamine depletion, STN-HFS
did not affect VGLUT1-3 expression. These data are rather
surprising since we reported in previous microdialysis
study that in intact rats STN-HFS increases extracellular
glutamate in the striatum, the globus pallidus and the
SNr [14-16,34]. However, the duration of stimulation
used here was longer than that used in our previous
studies. Thus, we can speculate that increase of extracellu-
lar glutamate levels induced by STN-HFS in physiological
conditions mainly involves non vesicular release. By con-
trast, after 6-OHDA lesions, STN-HFS induced an increase
in VGLUT1-3 expression in almost all the structures ana-
lyzed. In these DA depleted conditions, we cannot exclude
the possibility that the balance between non vesicular and
vesicular release of glutamate is disturbed, involving more
glutamate transporters on both neurons and glia [50,51].
Indeed, it is well documented that following DA nigrostria-
tal lesion, there is an increase in the number of glial cells,
including astrocytes and microglia. Therefore, the non
vesicular release may be due to an increase in membrane
transporters, such as glial glutamate transporters (GLT1
and GLAST) and the neuronal glutamate transporter
EEAC1 [55,63,64]. Thus, our previous findings concerning
increased extracellular glutamate levels in the striatum, glo-
bus pallidus and SNr of 6-OHDA-lesioned rats [15,16,34]
are consistent and confirm that STN-HFS affects not only
its direct targets, but also more distant structures of the BG
network [32,33]. The mechanisms underlying the thera-
peutic effects of STN-HFS are not fully elucidated. STN
neuron inhibition by HFS, with loss of the drive of the
internal part of the globus pallidus and disinhibition of the
thalamus (VL/VM), would be consistent with the classical
BG model [59,65]. However, far more complex effects and
circuitry are probably involved. For example, the direct
activation of nearby thalamostriatal and pallidonigral fibres
[16,66] or direct or antidromic cortex activation [67,68].
These mechanisms might lead to corticostriatal fiber activa-
tion and the observed increase in VGLUT1 levels.
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Similarly, the increase in VGLUT2 levels induced
here by STN-HFS may reflect a release of the classical
thalamic inhibition induced by dopamine lesions. As
VGLUT2 is found mostly in the thalamostriatal neu-
rons specifically affected by DA depletion, these data
strongly suggest a major role for this pathway in the
therapeutic effects of STN-HFS in PD [69,70]. How-
ever, the normalization of VGLUT2 levels we observed
in the somatosensory and premotor cortices may also
play a non negligeable role in these effects of STN-
HFS.
Interestingly, VGLUT2 was also overexpressed in the
SNr following STN-HFS in 6-OHDA-lesioned rats. As
VGLUT2 is the only VGLUT expressed by STN gluta-
matergic projections to the SNr [71], this confirms our
hypothesis that information transmission via the trans-
subthalamic pathway is not completely blocked during
STN-HFS [15,16,31,32,67,68] although the effect on
VGLUT2 expression in the SNr might also be mediated
by the modulation of thalamic afferents during STN-
HFS.
VGLUT3 is expressed in striatal cholinergic interneu-
rons linked to the dopaminergic, GABAergic and gluta-
matergic systems in the cortico-BG-cortical loop [38]. It is
therefore unsurprising that STN-HFS, which affects the
whole BG network, affects VGLUT3 expression in the
striatum and related structures, such as the cortex, hippo-
campus, nucleus accumbens, thalamus (VL/VM) and
amygdala. Indeed, STN-HFS has been reported to affect
not only dopamine, glutamate and GABA [14-16,34,36,68]
but also serotonin and cholinergic transmissions [72-74].
Consequently, it is difficult to explain the role of VGLUT3
in STN-HFS mechanisms. However, VGLUT3 in choliner-
gic interneurons has been shown to increase acetylcholine
tone and to release both glutamate and acetylcholine [18].
This mechanism might explain the efficacy of STN-HFS,
via complex modulation of the BG network [32,33].
Conclusion
In conclusion, this is the first study of the expression of
the three VGLUT subtypes in various brain structures in
control and 6-OHDA-lesioned rats subjected to STN-
HFS. We know that all the three types of VGLUTs are
expected to be found in axon terminals and that immu-
noradioautography cannot really disclose between neur-
onal vs. axonal vs. glial expression of VGLUTs. In situ
hybridization looking for different VGLUT transcripts
will probably provide some added morphological value to
our present study. These experiments are planned in our
lab. However, our present data can suggest that STN-
HFS may achieve its therapeutic effect, at least in part,
through normalization of the thalamostriatal and the
thalamocortical pathways.
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